BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 26.00
-0.25 (-0.95%)
Sep 8, 2026, 1:30 PM CST
BioGend Therapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 236.58 | 222.34 | 167.65 | 109.91 | 31.45 | 9.27 | |
Revenue Growth | 21.31% | 32.62% | 52.53% | 249.51% | 239.26% | 565.40% |
Cost of Revenue | 69.4 | 62.18 | 37.14 | 20.29 | 8.67 | 6.21 |
Gross Profit | 167.18 | 160.16 | 130.51 | 89.62 | 22.78 | 3.06 |
Selling, General & Admin | 146.11 | 145.41 | 124.04 | 95.16 | 75.73 | 54.09 |
Research & Development | 111.57 | 124.45 | 128.72 | 171 | 166.27 | 113.27 |
Operating Expenses | 259.05 | 270.65 | 252.77 | 266.16 | 241.99 | 167.37 |
Operating Income | -91.87 | -110.5 | -122.26 | -176.54 | -219.21 | -164.31 |
Interest Expense | -0.13 | -0.15 | -0.22 | -0.26 | -0.09 | -0.02 |
Interest & Investment Income | 8.64 | 8.04 | 6.07 | 6.92 | 4.59 | 2.88 |
Earnings From Equity Investments | -1.95 | -1.84 | -2.46 | -0.84 | - | -11.35 |
Currency Exchange Gain (Loss) | 0.07 | 0.11 | -0 | 0.03 | 0.07 | 0.51 |
Other Non Operating Income (Expenses) | 0.69 | 0.73 | 0.62 | 1.46 | 0.74 | 0.87 |
EBT Excluding Unusual Items | -84.55 | -103.61 | -118.25 | -169.22 | -213.9 | -171.4 |
Gain (Loss) on Sale of Investments | - | - | -10 | - | - | 26.7 |
Other Unusual Items | - | - | - | - | - | 0.44 |
Pretax Income | -84.55 | -103.61 | -128.25 | -169.22 | -213.9 | -144.27 |
Income Tax Expense | -8.31 | -8.31 | -8.31 | -8.3 | -8.4 | - |
Earnings From Continuing Operations | -76.24 | -95.3 | -119.94 | -160.92 | -205.5 | -144.27 |
Minority Interest in Earnings | 8.4 | 10.69 | 3.47 | 4.59 | 21.04 | 5.78 |
Net Income | -67.84 | -84.61 | -116.47 | -156.33 | -184.46 | -138.49 |
Net Income to Common | -67.84 | -84.61 | -116.47 | -156.33 | -184.46 | -138.49 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 125 | 123 | 123 | 120 | 103 | 101 |
Shares Outstanding (Diluted) | 125 | 123 | 123 | 120 | 103 | 101 |
Shares Change | 1.75% | - | 2.32% | 16.69% | 1.77% | 15.90% |
EPS (Basic) | -0.54 | -0.69 | -0.95 | -1.30 | -1.79 | -1.37 |
EPS (Diluted) | -0.54 | -0.69 | -0.95 | -1.30 | -1.79 | -1.37 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -50.17 | -65.52 | -99.56 | -164.76 | -186.96 | -137.47 |
Free Cash Flow Per Share | -0.40 | -0.53 | -0.81 | -1.37 | -1.81 | -1.36 |
Gross Margin | 70.67% | 72.03% | 77.85% | 81.54% | 72.44% | 33.00% |
Operating Margin | -38.83% | -49.70% | -72.93% | -160.63% | -697.11% | -1772.67% |
Profit Margin | -28.67% | -38.05% | -69.47% | -142.23% | -586.58% | -1494.07% |
Free Cash Flow Margin | -21.20% | -29.47% | -59.38% | -149.91% | -594.54% | -1483.13% |
EBITDA | -46.22 | -64.41 | -74.76 | -125.21 | -170.87 | -137.9 |
EBITDA Margin | -19.54% | -28.97% | -44.59% | -113.92% | - | - |
D&A For EBITDA | 45.65 | 46.09 | 47.5 | 51.33 | 48.35 | 26.41 |
EBIT | -91.87 | -110.5 | -122.26 | -176.54 | -219.21 | -164.31 |
EBIT Margin | -38.83% | -49.70% | -72.93% | -160.63% | - | - |